Business Context and Reporting Period
This Form 8-K is a current report filed by Miragen Therapeutics, Inc. (not Viridian Therapeutics, Inc.) on December 6, 2018, regarding events occurring on December 4 and December 5, 2018. The company is a Delaware corporation headquartered in Boulder, Colorado, and is classified as an emerging growth company.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The report focuses exclusively on corporate governance changes.
Material Changes
- Resignation of Director: Effective December 4, 2018, Bruce L. Booth, DPhil., resigned from the Board of Directors and all associated committees.
- Reason for Departure: The resignation was not the result of any disagreement with the company regarding operations, policies, or practices.
- Board Appointments:
- Jeffrey S. Hatfield was appointed as Chairman of the Board.
- Arlene M. Morris was appointed as a member of the Audit Committee.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future performance. No specific risks or contingencies were disclosed in this report other than the standard disclosure regarding the director's departure. A press release detailing these events was issued on December 5, 2018, and is included as Exhibit 99.1.
Investor Verification Checklist
- Verify the current composition of the Board of Directors and Audit Committee following the appointments of Mr. Hatfield and Ms. Morris.
- Review the press release (Exhibit 99.1) for any additional context regarding Dr. Booth's departure not included in the 8-K summary.
- Confirm the company's status as an emerging growth company and any implications for financial reporting standards.